Stephanie Schwalm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stephanie Schwalm has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Josef Pfeilschifter
University Hospital, pharmazentrum, Institute of General Pharmacology and Toxicology Goethe University Frankfurt am Main Germany
2 shared publicationsAleksandra Zivkovic
Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, D-40225, Duesseldorf, Germany
1 shared publication- Andrea Huwiler
Institute of Pharmacology, University of Bern, Inselspital, INO-F, CH-3010 Bern, Switzerland
1 shared publication Anke Oftring
University Hospital, pharmazentrum, Institute of General Pharmacology and Toxicology Goethe University Frankfurt am Main Germany
1 shared publicationBisera Stepanovska Tanturovska
Institute of Pharmacology, University of Bern, Inselspital INO-F, CH-3010, Bern, Switzerland
1 shared publicationBritta Engelhardt
Theodor Kocher Institute, University of Bern, Freiestrasse 1, CH-3012, Bern, Switzerland
1 shared publication
Latest Publications
- Open Access
- 25 June 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (12) , e70768
Elevated Sphingosine Levels Suppress Profibrotic TGF ‐β Signaling via the PKC / miR ‐21/ SMAD7 Axis in Sphingosine Kinase 2‐Deficient Renal Fibroblasts and Unilateral Ureteral Obstruction‐Induced Kidney Fibrosis
Renal fibrosis is the final pathological outcome of chronic kidney disease and is characterized by an excessive accumulation of extracellular matrix (ECM), leading to tissue dysfunction and, ultimately, organ failure. In this study, we investigated the mechanism by which elevated intracellular sphingosine levels in sphingosine kinase 2‐deficient ( Sphk2 −/− ) fibroblasts and mice attenuate profibrotic TGF‐β signaling. Previously, we demonstrated that higher sphingosine levels suppress the expression of profibrotic factors in TGF‐β‐treated fibroblasts and a unilateral ureteral obstruction (UUO) mouse model by upregulating SMAD7, an inhibitor of TGF‐β/SMAD signaling. Here, we identified miR‐21 as a key post‐transcriptional regulator of SMAD7 and show that protein kinase C (PKC) inhibition—via sphingosine supplementation, SPHK2 depletion, or pharmacological PKC inhibitors—reduces miR‐21 expression. Mechanistically, this occurs through PKC‐dependent inhibition of AP1‐driven miR‐21 transcription. Analysis of human diabetic kidney tissue revealed a significant upregulation of miR‐21, contributing to ECM accumulation by suppressing SMAD7 protein expression, corroborating the critical role of miR‐21 in renal fibrosis. These findings suggest that targeting the sphingosine‐PKC‐miR‐21‐SMAD7 axis may offer a novel therapeutic approach for renal fibrosis.
- 25 June 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (12) , e70768
Open AccessElevated Sphingosine Levels Suppress Profibrotic TGF ‐β Signaling via the PKC / miR ‐21/ SMAD7 Axis in Sphingosine Kinase 2‐Deficient Renal Fibroblasts and Unilateral Ureteral Obstruction‐Induced Kidney Fibrosis
Renal fibrosis is the final pathological outcome of chronic kidney disease and is characterized by an excessive accumulation of extracellular matrix (ECM), leading to tissue dysfunction and, ultimately, organ failure. In this study, we investigated the mechanism by which elevated intracellular sphingosine levels in sphingosine kinase 2‐deficient ( Sphk2 −/− ) fibroblasts and mice attenuate profibrotic TGF‐β signaling. Previously, we demonstrated that higher sphingosine levels suppress the expression of profibrotic factors in TGF‐β‐treated fibroblasts and a unilateral ureteral obstruction (UUO) mouse model by upregulating SMAD7, an inhibitor of TGF‐β/SMAD signaling. Here, we identified miR‐21 as a key post‐transcriptional regulator of SMAD7 and show that protein kinase C (PKC) inhibition—via sphingosine supplementation, SPHK2 depletion, or pharmacological PKC inhibitors—reduces miR‐21 expression. Mechanistically, this occurs through PKC‐dependent inhibition of AP1‐driven miR‐21 transcription. Analysis of human diabetic kidney tissue revealed a significant upregulation of miR‐21, contributing to ECM accumulation by suppressing SMAD7 protein expression, corroborating the critical role of miR‐21 in renal fibrosis. These findings suggest that targeting the sphingosine‐PKC‐miR‐21‐SMAD7 axis may offer a novel therapeutic approach for renal fibrosis.
- 1 March 2021
- Published by Elsevier in Neuropharmacology
- Vol. 186, 108464
Novel compounds with dual S1P receptor agonist and histamine H3 receptor antagonist activities act protective in a mouse model of multiple sclerosis
- 1 March 2021
- Published by Elsevier in Neuropharmacology
- Vol. 186, 108464
Novel compounds with dual S1P receptor agonist and histamine H3 receptor antagonist activities act protective in a mouse model of multiple sclerosis